Cogent Biosciences (COGT) AI Stock Analysis

• Market Cap: $6.31B
• Dividend Yield: N/A
• Average Volume (3M): 1.81M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: N/A
• EPS Growth: 4.32%
• Country: US
• Employees: 205
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.60
• Shares Outstanding: 162,308,820
• 10 Day Avg. Volume: 1,625,758
• 30 Day Avg. Volume: 1,805,830
• PEG Ratio: -2.00
• Price to Book (P/B): 3.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.03
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.68K
• Enterprise Value/Ebitda: -18.74
• 1Y Price Target: $52.18
• Price Target Upside: 34.31% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): -2.04
• Revenue Forecast (FY): $24.70M

• Rating: 49 Neutral
• Price Target: $36.00 ▼(-7.34% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is held down primarily by development-stage financials (near-zero revenue, widening losses, and worsening cash burn) and limited valuation support (negative P/E, no dividend). Offsetting factors include positive trial results that could improve future fundamentals and a mixed technical picture with near-term softness but longer-term trend support.

Positive Factors

Robust pivotal clinical data for bezuclastinib

Multiple registration-directed pivotal trials (SUMMIT, APEX, PEAK) produced statistically significant, clinically meaningful results in 2025. Durable, positive phase 3 data materially de-risks the lead asset, underpinning a credible path to approvals and sustained commercial demand across KIT-mutant indications.

Regulatory momentum and expedited review pathways

Bezuclastinib has received Breakthrough Therapy Designation and NDAs have been accepted/entered RTOR, evidencing regulatory recognition. These programs accelerate review timelines and create constructive regulatory catalysts that materially shorten time-to-market and reduce approval uncertainty if trials remain consistent.

Strong liquidity position entering 2026

Cogent reported ~$900.8M in cash and equivalents at year-end 2025, providing a multiyear runway into planned commercial launches and operations. This sizeable liquidity lessens near-term financing pressure, supports building a commercial organization, and increases the chance management can execute launches without emergency dilution.

Negative Factors

No meaningful revenue; widening net losses

The company remains pre-commercial with essentially zero revenue and materially larger net losses through 2025. Structural unprofitability means future fundamental value depends almost entirely on regulatory approvals and successful launches; absent those outcomes, continued operating deficits will erode capital and shareholder value.

High and growing cash burn

Operating and free cash flow have worsened substantially, reflecting heavy investment in development and commercialization buildout. Persistent, large negative cash flows magnify reliance on capital markets, raise dilution risk, and mean the company's runway and strategic optionality hinge on near-term program successes.

Rising leverage and financing activity

Debt increased materially in 2025 and management completed convertible notes and equity offerings. Higher leverage and recent financings create fixed obligations and potential dilution via conversions or follow-on equity, raising financing risk if commercialization or approvals face setbacks and limiting balance-sheet flexibility.

Cogent Biosciences Business Overview & Revenue Model

Company Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Cogent Biosciences makes money primarily through the development and commercialization of its precision therapies. The company generates revenue by advancing its drug candidates through clinical trials, securing regulatory approvals, and eventually launching these products into the market. Revenue streams include potential sales of approved therapies, milestone payments, and royalties from partnerships with larger pharmaceutical companies who may assist in the distribution and marketing of their products. Significant partnerships with other biotech firms and research institutions may also contribute to earnings by sharing resources, expertise, and financial support in the development of their therapies.

Cogent Biosciences Financial Statement Overview

Summary

Financials are very weak: revenue is essentially zero (2021–2025), losses have widened materially (net loss about -$72M in 2021 to about -$329M in 2025), and free cash flow burn has deepened (about -$60M to about -$266M). The main offset is a much larger 2025 equity base, but leverage increased sharply with debt rising to about $239M, elevating financing risk.

Income Statement

The income statement remains very weak: revenue is essentially zero in 2021–2025 (annual reports), while losses have expanded materially (net loss worsening from about $72M in 2021 to about $329M in 2025). Profitability is structurally negative, reflecting a business still in heavy investment mode with no meaningful commercial scale yet, and the loss trajectory is moving in the wrong direction.

Balance Sheet

The balance sheet is mixed but comparatively more stable. Equity has increased sharply (from roughly $256M in 2024 to about $636M in 2025), providing a larger capital base. However, debt rose significantly in 2025 (to about $239M), lifting leverage (debt-to-equity moved from ~0.07 in 2024 to ~0.38 in 2025). Returns on shareholders’ capital remain deeply negative due to sizable losses.

Cash Flow

Cash flow is pressured by ongoing cash burn. Operating cash flow and free cash flow are consistently negative and have deteriorated in absolute terms (free cash flow from about -$60M in 2021 to about -$266M in 2025). A positive free cash flow growth figure in 2025 is not indicative of strength given free cash flow is still meaningfully negative, and cash generation is not yet covering the business’s cost structure.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-4.62M	0.00	0.00	0.00	0.00
EBITDA	-328.74M	-271.59M	-204.54M	-141.96M	-73.56M
Net Income	-328.94M	-255.86M	-192.41M	-140.24M	-72.27M
Balance Sheet
Total Assets	937.61M	327.90M	313.44M	300.81M	232.09M
Cash, Cash Equivalents and Short-Term Investments	900.76M	287.08M	265.71M	259.28M	219.68M
Total Debt	253.15M	17.47M	18.85M	19.65M	3.15M
Total Liabilities	301.24M	71.61M	55.63M	45.08M	17.91M
Stockholders Equity	636.37M	256.29M	257.80M	255.74M	214.18M
Cash Flow
Free Cash Flow	-266.00M	-208.36M	-156.42M	-125.50M	-60.48M
Operating Cash Flow	-264.44M	-207.79M	-153.62M	-118.64M	-58.76M
Investing Cash Flow	-399.53M	38.28M	-97.82M	-124.72M	-1.72M
Financing Cash Flow	878.23M	214.45M	163.54M	163.56M	37.98M

Cogent Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 38.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COGT, the sentiment is Positive. The current price of 38.85 is above the 20-day moving average (MA) of 37.66, above the 50-day MA of 37.68, and above the 200-day MA of 21.10, indicating a bullish trend. The MACD of 0.46 indicates Negative momentum. The RSI at 54.63 is Neutral, neither overbought nor oversold. The STOCH value of 77.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COGT.

Cogent Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	69 Neutral	$1.65B	10.54	20.75%	―	21.13%	50.86%
BEAM	63 Neutral	$2.90B	-28.02	-8.11%	―	-84.07%	-157.71%
IMCR	53 Neutral	$1.64B	-45.59	-9.59%	―	27.51%	38.72%
IDYA	52 Neutral	$2.83B	-24.71	-10.92%	―	5376.27%	20.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COGT	49 Neutral	$6.31B	-15.18	-73.70%	―	―	4.32%
IRON	43 Neutral	$2.54B	-11.12	-34.78%	―	―	-34.96%

Cogent Biosciences Corporate Events

Cogent Biosciences Reports Positive Clinical Trial Results

On December 6 and 8, 2025, Cogent Biosciences announced significant results from their clinical trials of bezuclastinib for systemic mastocytosis. The SUMMIT trial showed that bezuclastinib led to substantial improvements in patients with nonadvanced systemic mastocytosis, while the APEX trial demonstrated positive outcomes for those with advanced systemic mastocytosis. These results bolster Cogent’s position in the biotech industry and pave the way for a new drug application to the FDA, with potential implications for patients and stakeholders.

The most recent analyst rating on (COGT) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Cogent Biosciences stock, see the COGT Stock Forecast page.

Cogent Biosciences Completes $230M Convertible Notes Offering

On November 18, 2025, Cogent Biosciences completed a public offering of $230 million in Convertible Senior Notes due 2031. This financial move is designed to strengthen the company’s capital structure and potentially enhance its market position by providing flexibility for future growth and operations. The Notes, which are unsecured and senior obligations, offer conversion options under specific conditions and are subject to redemption and repurchase terms. The offering could impact stakeholders by influencing the company’s financial strategies and market dynamics.

The most recent analyst rating on (COGT) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Cogent Biosciences stock, see the COGT Stock Forecast page.